Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · HIKAL LIMITED · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
HIKAL LIMITED
NSE: HIKAL · BSE: 524735
NSE: HIKAL · BSE: 524735
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
HIKAL LIMITED
StateQ1 FY27 filed
Last close · 28 Oct 2026₹202.25
Market cap₹2.5k cr
TTM P/E · P/B · EV/EBITDA— · 2.08 · 18.7
HIKAL LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,943 | 2,023 | 1,785 | 1,860 | 1,713 |
| EBITDA (ex other income) | 341 | 257 | 267 | 328 | 135 |
| margin % | 17.5 | 12.7 | 15.0 | 17.7 | 7.9 |
| Owners' profit | 0 | 78 | 0 | 0 | (49) |
| EPS, as reported (₹) | 13.02 | 6.36 | 5.64 | 7.36 | (3.96) |
| ROE % · ROCE % | 15.0 · 17.3 | 6.9 · 8.9 | 5.9 · 8.8 | 7.2 · 11.4 | (4.1) · (1.0) |
| Debt / equity (x) | 0.63 | 0.66 | 0.69 | 0.60 | 0.57 |
| Cash from operations | 294 | 315 | 187 | 280 | 302 |
| Capex | (273) | (303) | (204) | (137) | (148) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · HIKAL LIMITED · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 453 | 448 | 552 | 380 | 319 | 494 | 519 | 403 |
| Profit before tax | 25 | 24 | 68 | (30) | (47) | (9) | 8 | (10) |
| Net profit | 18 | 17 | 50 | (22) | (35) | (6) | 14 | (7) |
| EPS (₹) | 1.48 | 1.39 | 4.07 | (1.82) | (2.83) | (0.48) | 1.17 | (0.60) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceuticals | 1,021 | 59.6 |
| Crop Protection | 535 | 31.2 |
| Crop protection | 157 | 9.2 |
| Total, before eliminations | 1,713 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 2.1 | 3.1 | 56 of 163 | 65% |
| ROCE | (4.6) | 10.8 | 162 of 183 | 12% |
| ROE | (4.1) | 9.8 | 149 of 166 | 10% |
| Debt / Equity | 0.6 | 0.2 | 141 of 166 | 15% |
| EBITDA margin | 11.8 | 17.5 | 110 of 165 | 34% |
| Revenue growth | 5.9 | 16.3 | 109 of 161 | 33% |
| Profit growth | 67.0 | 30.9 | 51 of 158 | 68% |
| Market cap | 2498 | 806 | 70 of 181 | 62% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · HIKAL LIMITED · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 26 Oct 2026 · Hikal schedules Q2 and H1 FY27 earnings conference call | board shareholder meetings | low | — | — |
| 26 Oct 2026 · Board to approve Hikal's September 2026 quarterly results | results | low | — | — |
| 13 Oct 2026 · Newspaper notice on special window to dematerialise old physical shares | compliance | minimal | — | — |
| 7 Oct 2026 · Routine RTA compliance certificate for Q2 FY27 | compliance | minimal | — | — |
| 1 Oct 2026 · Hikal: Founder ends Chairman term, director resigns, new divisional CEO appointed | management changes | critical | — | — |
| 1 Oct 2026 · Founder ends Executive Chairman term, director resigns, new CEO appointed | management changes | critical | — | — |
| 29 Sept 2026 · Hikal gets Crisil ESG rating of 65 for FY26 | business updates | medium | — | — |
| 28 Sept 2026 · Trading window closed from Oct 1 until Q2 results | compliance | minimal | — | — |
| 23 Sept 2026 · Shareholders approve Sameer Hiremath as Chairman and MD for 5 years | compliance | low | — | — |
| 23 Sept 2026 · Hikals 38th AGM concludes, all 6 resolutions passed including dividend | board shareholder meetings | low | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in